Coral Laboratories Share Price
Small Cap | Pharmaceuticals and health care | BSE: 524506
₹757.60 
20.05 (2.72 %)
Last Updated: 13 Mar 2025 12:00 AM
BEARISH
Overview
Open (₹) 731.10
High (₹) 769.00
Low (₹) 730.00
Prev. Close (₹) 737.55
Volume 719
VWAP (₹) 729.72
ROCE (%) 11.55
Industry P/E 43.95
TTM P/E 9.98
P/B Ratio 1.52
Market Cap (₹) Cr.270.66
Dividend Yield (%)0.26
EPS (₹) 44.19
ROE8.89%
Sales Growth (%) 7.09
Profit Growth (%)144.97
Day Range
769.00769.00
52 Week Range
355.00999.00
Historical Returns
Returns (6M)
-19.92 %
Returns (1Y)
83.02 %
Returns (3Y)
176.45 %
Returns (5Y)
480.31 %
Returns (6M)
-19.92 %
Returns (1Y)
83.02 %
Returns (3Y)
176.45 %
Returns (5Y)
480.31 %
SWOT Analysis
- Growth in Net Profit Margin (QoQ)
- Strong long-term momentum: Price above long-term moving averages (EMA_200)
- Price above the pivot point indicates bullish sentiment.
Technicals
Technical Rating
BEARISHRSI 64.77
MFI 69.29
ATR 41.02
Commodity Channel Index -131.53
ROC125 -20.81
ROC21 -1.69
Williams %R -73.81
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 758.11 | 778.93 | 801.96 | 735.08 | 714.26 | 691.23 | 670.41 |
| Week Ago | 787.34 | 794.97 | 799.64 | 782.67 | 775.04 | 770.37 | 762.74 |
| Month Ago | 767.90 | 783.95 | 807.90 | 743.95 | 727.90 | 703.95 | 687.90 |
EMA & SMA
757.60
Current Price
Bullish Moving Averages
2
Bearish Moving Averages
18
5 Day 775.33
9 Day 781.88
10 Day 786.91
12 Day 766.00
14 Day 769.40
20 Day 770.42
26 Day 766.22
50 Day 771.34
100 Day 797.69
200 Day 753.47
Deals & Announcements
Bulk and Block Deals
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| NEELAM MITTAL | bulk | Sell | 24 May, 2024 | ₹539.62 | 1,100 | BSE |
| NEELAM MITTAL | bulk | Buy | 24 May, 2024 | ₹537.82 | 21,709 | BSE |
| VAIBHAV RAJENDRA DOSHI | bulk | Sell | 08 Sept, 2022 | ₹276.48 | 19,050 | BSE |
| GUTTIKONDA VARA LAKSHMI | bulk | Sell | 13 Dec, 2021 | ₹286.89 | 20,000 | BSE |
| GUTTIKONDA VARA LAKSHMI | bulk | Buy | 20 Apr, 2020 | ₹164.95 | 20,000 | BSE |
Insider Trading
| Date | Name | Action | Avg. Price | Quantity | Deal Value |
|---|---|---|---|---|---|
| 22 Feb, 2022 | CHETAN NAVINCHANDRA DOSHI | Disposal | ₹ | BSE |
Corporate Actions
| Announcement Date | Subject | Ex - Date | Record Date |
|---|---|---|---|
| 13 Jul, 2024 | Rs.2.0000 per share(20%)Final Dividend | 20 Sept, 2024 | 01 Jan, 1970 |
Announcements
| Date | Source | Detail |
|---|---|---|
| 13 Feb, 2025 | BSE India | In accordance with amendments to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Third Amendment) Regulations, 2024 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024, read with BSE Circular No. 20250102-4 the Integrated Filing (Financial) for the quarter and nine months ended 31st December, 2024 is enclosed. |
| 13 Feb, 2025 | BSE India | To consider and adopt the Unaudited Standalone Financial Results for the quarter and nine months ended December 31 2024, with the Limited Review Report |
| 13 Feb, 2025 | BSE India | To consider and adopt the Unaudited Standalone Financial Results for the quarter and nine months ended December 31 2024, with the Limited Review Report in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |
| 05 Feb, 2025 | BSE India | CORAL LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 ,inter alia, to consider and approve Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2024 |
| 03 Jan, 2025 | BSE India | Change Of Name Of Registrar And Share Transfer Agent Of The Company |
| 19 Dec, 2024 | BSE India | Dear Sir/ Madam,\r\n\r\nPursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015\r\n('SEBI (LODR) Regulations') this is to inform you that BSE Ltd. Vide email dated December 13, 2024, imposed penalty of Rs. 45,000/- (Rupees Fourty Five Thousand only) for delay in submission of Limited Review Report which is part of Financial Result which was missed inadvertently. \r\n\r\nKindly acknowledge receipt and record the same\r\n |
| 26 Nov, 2024 | BSE India | Submission of Limited Review Report missed inadvertently in financial result submitted on 14th November, 2024\r\n |
| 14 Nov, 2024 | BSE India | Dear Sir/Madam,\r\n\r\nSub: Disclosure under Reg 23(9) of SEBI (LODR) Regulations, 2015\r\n\r\nPursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit disclosure of Related Party Transactions for the half year ended September 30, 2024, in accordance with the applicable Accounting Standards.\r\n\r\nThis is for your information and record.\r\n |
| 14 Nov, 2024 | BSE India | \r\nPursuant Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith following: \r\n\r\n1. The Unaudited Standalone Financial Results of the Company for the quarter and half year ended September 30, 2024.\r\n2. Limited Review Report thereon.\r\n3. Statement of Asset & Liabilities for the half year ended September 30,2024.\r\n4. Cash Flow Statements for the half year ended September 30,2024.\r\n |
| 14 Nov, 2024 | BSE India | In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable provisions, the Board of Directors of the Company in its meeting held on Thursday, 14th November 2024 at the Corporate Office of the Company situated at 3B, Patanwala Compound, Opp. Shreyas Cinema, L.B.S. Marg, Ghatkopar (W), Mumbai- 400086 at 2:30 P.M, has inter alia considered and approved: \r\n\r\n1. The Unaudited Standalone Financial Results along with Statement of Asset & Liabilities and Cash Flow Statement for the quarter and half year ended September 30, 2024 and took note of the Limited Review Report submitted by M A Parekh & Associates, Statutory Auditor of the Company.\r\n\r\n\r\n\r\n |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results | -- | 06 Feb, 2025 | 13 Feb, 2025 |
| Quarterly Results | -- | 07 Nov, 2024 | 14 Nov, 2024 |
| Quarterly Results | -- | 07 Aug, 2024 | 14 Aug, 2024 |
| Others | -- | 07 Aug, 2024 | 09 Aug, 2024 |
| Others | -- | 06 Jul, 2024 | 13 Jul, 2024 |
| Audited Results | -- | 20 May, 2024 | 23 May, 2024 |
| Others | Inter alia, to consider and approve the Appointment of Company Secretary. | 19 Apr, 2024 | 24 Apr, 2024 |
| Others | Inter alia, 1. To appoint Company Secretary and Compliance Officer of the company. | 01 Mar, 2024 | 08 Mar, 2024 |
| Quarterly Results | -- | 08 Feb, 2024 | 14 Feb, 2024 |
| Quarterly Results | -- | 03 Nov, 2023 | 09 Nov, 2023 |
Share Holding Pattern
| Owner Name | Dec, 2024 | Sept, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
|---|
About Coral Laboratories
Coral Laboratories is a Public Limited Listed company incorporated on 06/02/1997 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24231MH1997PLC422233 and registration number is 422233. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 83.66 Cr. and Equity Capital is Rs. 3.57 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Not Applicable
Founded
1997
Managing Director
-- --
NSE Symbol
--
Coral Laboratories Management
| Name | Designation |
|---|---|
| Mrs. Sushma Kadkade | Director & CFO |
| Ms. Pooja Hindia | Independent Director |
| Dr. Saurabh Shah | Independent Director |
| Mr. Malay Doshi | Independent Director |
| Mr. Rajendrasinh Rana | Director |
| Mr. Girish M Dhameja | Whole Time Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| Sun Pharmaceutical Industries | ₹4,03,916.05 | ₹1,683.45  ₹1,676.85(0.39%) | ₹1,376.750 - ₹1,960.200 |
| Divi's Laboratories | ₹1,49,205.29 | ₹5,620.45  ₹5,667.15(-0.82%) | ₹3,350.050 - ₹6,448.750 |
| Cipla | ₹1,18,065.23 | ₹1,461.90 ₹1,454.30(0.52%) | ₹1,317.600 - ₹1,702.000 |
| Torrent Pharmaceuticals | ₹1,03,430.62 | ₹3,056.05 ₹3,096.50(-1.31%) | ₹2,488.000 - ₹3,589.950 |
| Dr. Reddy's Laboratories | ₹92,453.48 | ₹1,107.95 ₹1,105.15(0.25%) | ₹1,093.000 - ₹1,420.200 |
FAQs on Coral Laboratories
What is the share price of Coral Laboratories?
The share price of Coral Laboratories on 13 Mar, 2025 is ₹ 757.60.
What is 52W high and 52W low share price of Coral Laboratories?
The highest and lowest 52W share prices of Coral Laboratories are ₹ 999.000 and ₹ 355.000
What is the market cap of Coral Laboratories?
The market capitalization of Coral Laboratories as of 13 Mar, 2025 is ₹ 270.66 Crores
What is the P/E ratio of Coral Laboratories?
The current P/E ratio of Coral Laboratories as of 13 Mar, 2025 is 43.95
What is the PB ratio of Coral Laboratories?
The PB ratio of Coral Laboratories as of 13 Mar, 2025 is 1.52
Top Gainers
₹41.02
₹34.29 (0.20%)
₹8.84
₹7.37 (0.20%)
₹6.97
₹5.81 (0.20%)
₹194.70
₹162.25 (0.20%)
Top Losers
₹13.75
₹135.15 (-0.90%)
₹9.60
₹12.00 (-0.20%)
₹9.80
₹93.55 (-0.90%)
₹0.99
₹4.77 (-0.79%)
Market Indices
Sensex
₹73,828.91
₹74,029.76 (0.00%)